GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (XTAE:BLRX) » Definitions » EPS without NRI

BioLine Rx (XTAE:BLRX) EPS without NRI : ₪-0.23 (TTM As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is BioLine Rx EPS without NRI?

BioLine Rx's earnings per share without non-recurring items for the three months ended in Dec. 2023 was ₪-0.04. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.23.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 25.10% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 33.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for BioLine Rx's EPS without NRI or its related term are showing as below:

XTAE:BLRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 8.9   Med: 26.25   Max: 45.3
Current: 25.1

During the past 13 years, BioLine Rx's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 45.30% per year. The lowest was 8.90% per year. And the median was 26.25% per year.

XTAE:BLRX's 3-Year EPS without NRI Growth Rate is ranked better than
74.58% of 1298 companies
in the Biotechnology industry
Industry Median: 5.45 vs XTAE:BLRX: 25.10

BioLine Rx's EPS (Diluted) for the three months ended in Dec. 2023 was ₪-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.23.

BioLine Rx's EPS (Basic) for the three months ended in Dec. 2023 was ₪-0.04. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ₪-0.23.


BioLine Rx EPS without NRI Historical Data

The historical data trend for BioLine Rx's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx EPS without NRI Chart

BioLine Rx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.76 -0.37 -0.14 -0.14 -0.16

BioLine Rx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.04 -0.08 -0.08 -0.04

Competitive Comparison of BioLine Rx's EPS without NRI

For the Biotechnology subindustry, BioLine Rx's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioLine Rx's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where BioLine Rx's PE Ratio without NRI falls into.



BioLine Rx EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪-0.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioLine Rx  (XTAE:BLRX) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


BioLine Rx EPS without NRI Related Terms

Thank you for viewing the detailed overview of BioLine Rx's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


BioLine Rx (XTAE:BLRX) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

BioLine Rx (XTAE:BLRX) Headlines

From GuruFocus

BioLineRx to Report First Quarter 2023 Results on May 24, 2023

By PRNewswire PRNewswire 05-17-2023